ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $18.00 → $24.00 | Hold → Buy | Stifel |
| 5/8/2024 | $15.00 → $20.00 | Neutral → Buy | ROTH MKM |
| 10/20/2023 | $12.00 | Neutral | ROTH MKM |
| 9/12/2023 | Buy → Neutral | BTIG Research | |
| 9/12/2023 | Buy → Hold | Stifel | |
| 7/19/2023 | $27.00 | Buy | BTIG Research |
| 3/4/2022 | $41.00 → $45.00 | Hold → Buy | Stifel |
Building on Positive Momentum from Compelling Combination of Profitable, Above-Market Growth with a Stronger Financial Profile Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third quarter 2024 net sales of $196.6 million, an increase of 7% on a reported and constant currency basis compared to third quarter 2023 U.S. Spine Fixation1 net sales growth of 18% compared to third quarter 2023, driven by distribution expansion and further penetration in existi
Company to Host Conference Call on Thursday, November 7, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2024 financial results on Thursday, November 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,
Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% compared to second quarter 2023, marking six consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 12% compared to second quarter 2023, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Stifel 2024 Healthcare Conference in New York, NY, November 18, 2024, fireside chat at 8:35 AM Eastern Time Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach, CA, December 9, 2024, fireside chat at 8:00 AM Pacific Time Live webcasts and replays, when available, can be found under "Events & Presentations" in the Investors section of the Orthofix website at https://ir.orthofix.com/events-and-presentations/.
Building on Positive Momentum from Compelling Combination of Profitable, Above-Market Growth with a Stronger Financial Profile Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third quarter 2024 net sales of $196.6 million, an increase of 7% on a reported and constant currency basis compared to third quarter 2023 U.S. Spine Fixation1 net sales growth of 18% compared to third quarter 2023, driven by distribution expansion and further penetration in existi
New Financing Replaces Existing Term Loan and Seeks to Further Optimize the Company's Capital Structure to Support Long-Term, Profitable Growth Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the entry into a new credit agreement providing the Company with up to $275 million in a senior-secured term loan with a 48-month interest only period. The term loan is agented by Oxford Finance LLC ("Oxford") and provides non-dilutive capital and financial flexibility to support Orthofix's continued focus on profitable growth. The proceeds from the initial funding of the term loan will be used to retire the Company's existing credit facility and pay r
8-K - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
10-Q - Orthofix Medical Inc. (0000884624) (Filer)
The Rodeo Telescopic Nail is a device indicated to surgically treat deformities or fractures in patients suffering from osteogenesis imperfecta (OI). The nail implant serves to stabilize the patient's limb while also elongating (or telescoping) to accommodate the natural growth of pediatric patients.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for ZoomInfo Technologies Inc. (NASDAQ:ZI) from $24 to $15. Piper Sandler analyst Brent Bracelin downgraded the stock from Overweight to Neutral. ZoomInfo Technologies shares fell 3.6% to close at $16.02 on Tuesday. See how other analysts view this stock. Baird boosted the price target for Datadog, Inc. (NASDAQ:DDOG) from $130 to $140. Baird analyst William Power upgraded the stock from Neutral to Outperform. Datadog shares fell 11.5% to close at $112.40 on Tuesda
Roth MKM analyst Jason Wittes upgrades Orthofix Medical (NASDAQ:OFIX) from Neutral to Buy and raises the price target from $15 to $20.
4 - Orthofix Medical Inc. (0000884624) (Issuer)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously
ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously
ROTH MKM initiated coverage of Orthofix with a rating of Neutral and set a new price target of $12.00
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Michael Finegan as Chair of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624766470/en/Michael Finegan, Chair of the Orthofix Board of Directors. (Photo: Business Wire) Finegan was appointed to the Orthofix Board in December 2023. He is CEO at Acera Surgical, a bioscience company developing and commercializing a portfolio of fully engineered synthetic materials for soft tissue repair and regenerative medicine. Prior to joining Acera, Finegan spent 14 years at Orthofix where he served